Merck Net Debt from 2010 to 2024

MRK Stock

USD 99.86 2.42 2.48%

Merck Net Debt yearly trend continues to be quite stable with very little volatility. Net Debt may rise above about 30.8 B this year. Net Debt is the total debt of Merck Company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. View All Fundamentals

Net Debt

First Reported

1985-12-31

Previous Quarter

26.4 B

Current Value

23.5 B

Quarterly Volatility

8.7 B

Black Monday

Oil Shock

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Merck financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Merck's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.8 B, Interest Expense of 1.2 B or Total Revenue of 32.4 B, as well as many indicators such as Price To Sales Ratio of 4.32, Dividend Yield of 0.0246 or PTB Ratio of 6.92. Merck financial statements analysis is a perfect complement when working with Merck Valuation or Volatility modules.

Check out the analysis of Merck Correlation against competitors.

Latest Merck's Net Debt Growth Pattern

Below is the plot of the Net Debt of Merck Company over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. Merck's Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Merck's overall financial position and show how it may be relating to other accounts over time.

Net Debt

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Net Debt

Timeline

Merck Net Debt Regression Statistics

	Arithmetic Mean	16,635,583,333
	Coefficient Of Variation	53.07
	Mean Deviation	6,535,482,222
	Median	17,990,000,000
	Standard Deviation	8,828,127,682
	Sample Variance	77935838.4T
	Range	31.2B
	R-Value	0.93
	Mean Square Error	11752020.6T
	R-Squared	0.86
	Slope	1,830,618,036
	Total Sum of Squares	1091101737.1T

Merck Net Debt History

	2024	30.8 B
	2023	29.4 B
	2022	18 B
	2021	25 B
	2020	23.7 B
	2019	16.7 B
	2018	17.1 B

Other Fundumenentals of Merck Company

Net Debt To E B I T D A

Merck Net Debt component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Accounts Payable	Short Term Investments	Capital Stock	Common Stock	Long Term Debt	Good Will	Treasury Stock	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Total Permanent Equity	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Accumulated Depreciation	Short Long Term Debt	Cash And Equivalents	Net Invested Capital	Net Working Capital
Total Assets		0.87	0.28	0.88	0.57	0.7	0.98	0.3	0.8	0.5	0.16	0.95	0.95	0.73	0.65	-0.27	0.44	-0.21	-0.22	0.19	0.35	0.22	0.36	0.31	-0.7	0.02	0.19	0.2	0.15
Total Stockholder Equity	0.87		-0.07	0.59	0.4	0.4	0.9	0.07	0.93	0.06	0.37	0.72	0.72	0.36	0.22	0.18	0.21	-0.26	0.23	-0.07	-0.02	0.1	0.61	0.48	-0.48	-0.37	-0.07	0.16	0.35
Net Debt	0.28	-0.07		0.57	0.74	0.83	0.18	0.11	-0.09	0.74	-0.2	0.42	0.42	0.74	0.71	-0.89	0.5	0.52	-0.58	0.54	0.82	0.58	-0.42	-0.26	-0.43	0.32	0.56	0.48	-0.1
Retained Earnings	0.88	0.59	0.57		0.65	0.83	0.84	0.26	0.5	0.81	0.01	0.9	0.9	0.91	0.89	-0.65	0.58	0.03	-0.48	0.37	0.65	0.37	0.04	0.04	-0.74	0.24	0.48	0.37	0.18
Net Receivables	0.57	0.4	0.74	0.65		0.88	0.53	0.06	0.44	0.57	-0.28	0.59	0.59	0.65	0.53	-0.61	0.7	0.54	-0.3	0.5	0.59	0.72	0.07	-0.26	-0.53	-0.05	0.6	0.62	0.2
Total Liab	0.7	0.4	0.83	0.83	0.88		0.64	0.35	0.4	0.76	-0.17	0.78	0.78	0.81	0.78	-0.77	0.56	0.25	-0.59	0.52	0.65	0.45	-0.05	-0.09	-0.75	0.28	0.46	0.38	-0.03
Total Current Assets	0.98	0.9	0.18	0.84	0.53	0.64		0.3	0.82	0.42	0.21	0.91	0.91	0.64	0.55	-0.18	0.4	-0.25	-0.12	0.15	0.24	0.18	0.38	0.33	-0.71	-0.06	0.18	0.16	0.19
Short Term Debt	0.3	0.07	0.11	0.26	0.06	0.35	0.3		0.11	0.28	-0.27	0.4	0.4	0.14	0.26	-0.23	0.03	-0.43	-0.48	0.19	-0.12	-0.34	-0.05	0.08	-0.63	0.74	-0.13	-0.42	-0.64
Intangible Assets	0.8	0.93	-0.09	0.5	0.44	0.4	0.82	0.11		0.08	0.15	0.65	0.65	0.29	0.16	0.19	0.28	-0.21	0.14	-0.05	-0.05	0.11	0.75	0.25	-0.47	-0.31	-0.09	0.14	0.22
Accounts Payable	0.5	0.06	0.74	0.81	0.57	0.76	0.42	0.28	0.08		-0.36	0.59	0.59	0.86	0.91	-0.91	0.64	0.27	-0.74	0.45	0.81	0.4	-0.33	-0.38	-0.64	0.54	0.59	0.41	-0.05
Short Term Investments	0.16	0.37	-0.2	0.01	-0.28	-0.17	0.21	-0.27	0.15	-0.36		0.14	0.14	-0.11	-0.14	0.39	-0.55	-0.48	0.36	-0.28	-0.27	-0.35	0.22	0.77	0.11	-0.4	-0.48	-0.3	0.08
Capital Stock	0.95	0.72	0.42	0.9	0.59	0.78	0.91	0.4	0.65	0.59	0.14		1.0	0.77	0.76	-0.42	0.38	-0.27	-0.43	0.3	0.38	0.19	0.24	0.29	-0.7	0.21	0.23	0.06	-0.03
Common Stock	0.95	0.72	0.42	0.9	0.59	0.78	0.91	0.4	0.65	0.59	0.14	1.0		0.77	0.76	-0.42	0.38	-0.27	-0.43	0.3	0.38	0.19	0.24	0.29	-0.7	0.21	0.23	0.06	-0.03
Long Term Debt	0.73	0.36	0.74	0.91	0.65	0.81	0.64	0.14	0.29	0.86	-0.11	0.77	0.77		0.93	-0.76	0.67	0.23	-0.52	0.41	0.88	0.56	-0.2	-0.09	-0.58	0.24	0.6	0.49	0.11
Good Will	0.65	0.22	0.71	0.89	0.53	0.78	0.55	0.26	0.16	0.91	-0.14	0.76	0.76	0.93		-0.83	0.51	0.07	-0.75	0.5	0.79	0.33	-0.2	-0.1	-0.56	0.49	0.51	0.28	-0.02
Treasury Stock	-0.27	0.18	-0.89	-0.65	-0.61	-0.77	-0.18	-0.23	0.19	-0.91	0.39	-0.42	-0.42	-0.76	-0.83		-0.55	-0.44	0.77	-0.56	-0.83	-0.46	0.51	0.43	0.51	-0.54	-0.67	-0.4	0.07
Property Plant Equipment	0.44	0.21	0.5	0.58	0.7	0.56	0.4	0.03	0.28	0.64	-0.55	0.38	0.38	0.67	0.51	-0.55		0.61	-0.23	0.39	0.71	0.84	-0.05	-0.6	-0.41	0.04	0.85	0.75	0.24
Current Deferred Revenue	-0.21	-0.26	0.52	0.03	0.54	0.25	-0.25	-0.43	-0.21	0.27	-0.48	-0.27	-0.27	0.23	0.07	-0.44	0.61		0.07	0.28	0.58	0.81	-0.33	-0.65	0.07	-0.25	0.66	0.85	0.43
Net Tangible Assets	-0.22	0.23	-0.58	-0.48	-0.3	-0.59	-0.12	-0.48	0.14	-0.74	0.36	-0.43	-0.43	-0.52	-0.75	0.77	-0.23	0.07		-0.51	-0.46	0.02	0.23	0.33	0.4	-0.82	-0.31	0.14	0.45
Total Permanent Equity	0.19	-0.07	0.54	0.37	0.5	0.52	0.15	0.19	-0.05	0.45	-0.28	0.3	0.3	0.41	0.5	-0.56	0.39	0.28	-0.51		0.43	0.31	0.0	-0.35	-0.3	0.25	0.41	0.25	-0.04
Long Term Debt Total	0.35	-0.02	0.82	0.65	0.59	0.65	0.24	-0.12	-0.05	0.81	-0.27	0.38	0.38	0.88	0.79	-0.83	0.71	0.58	-0.46	0.43		0.72	-0.42	-0.38	-0.31	0.18	0.74	0.69	0.18
Capital Surpluse	0.22	0.1	0.58	0.37	0.72	0.45	0.18	-0.34	0.11	0.4	-0.35	0.19	0.19	0.56	0.33	-0.46	0.84	0.81	0.02	0.31	0.72		-0.14	-0.47	-0.08	-0.29	0.82	0.84	0.39
Deferred Long Term Liab	0.36	0.61	-0.42	0.04	0.07	-0.05	0.38	-0.05	0.75	-0.33	0.22	0.24	0.24	-0.2	-0.2	0.51	-0.05	-0.33	0.23	0.0	-0.42	-0.14		0.15	0.01	-0.33	-0.33	-0.14	0.08
Long Term Investments	0.31	0.48	-0.26	0.04	-0.26	-0.09	0.33	0.08	0.25	-0.38	0.77	0.29	0.29	-0.09	-0.1	0.43	-0.6	-0.65	0.33	-0.35	-0.38	-0.47	0.15		-0.03	-0.22	-0.6	-0.43	0.01
Accumulated Depreciation	-0.7	-0.48	-0.43	-0.74	-0.53	-0.75	-0.71	-0.63	-0.47	-0.64	0.11	-0.7	-0.7	-0.58	-0.56	0.51	-0.41	0.07	0.4	-0.3	-0.31	-0.08	0.01	-0.03		-0.35	-0.17	-0.15	0.12
Short Long Term Debt	0.02	-0.37	0.32	0.24	-0.05	0.28	-0.06	0.74	-0.31	0.54	-0.4	0.21	0.21	0.24	0.49	-0.54	0.04	-0.25	-0.82	0.25	0.18	-0.29	-0.33	-0.22	-0.35		0.07	-0.34	-0.65
Cash And Equivalents	0.19	-0.07	0.56	0.48	0.6	0.46	0.18	-0.13	-0.09	0.59	-0.48	0.23	0.23	0.6	0.51	-0.67	0.85	0.66	-0.31	0.41	0.74	0.82	-0.33	-0.6	-0.17	0.07		0.67	0.34
Net Invested Capital	0.2	0.16	0.48	0.37	0.62	0.38	0.16	-0.42	0.14	0.41	-0.3	0.06	0.06	0.49	0.28	-0.4	0.75	0.85	0.14	0.25	0.69	0.84	-0.14	-0.43	-0.15	-0.34	0.67		0.64
Net Working Capital	0.15	0.35	-0.1	0.18	0.2	-0.03	0.19	-0.64	0.22	-0.05	0.08	-0.03	-0.03	0.11	-0.02	0.07	0.24	0.43	0.45	-0.04	0.18	0.39	0.08	0.01	0.12	-0.65	0.34	0.64

Click cells to compare fundamentals

About Merck Financial Statements

Merck investors utilize fundamental indicators, such as Net Debt, to predict how Merck Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.

	Last Reported	Projected for Next Year
Net Debt	29.4 B	30.8 B
Net Debt To EBITDA	4.25	4.46

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Merck Company is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Merck Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Merck Company Stock. Highlighted below are key reports to facilitate an investment decision about Merck Company Stock:

How To Invest In Merck

Details

Is Merck Stock a good investment?

Details

What is Merck's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Merck Correlation against competitors.

You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merck. If investors know Merck will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Merck listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.33)

Dividend Share

3.04

Earnings Share

4.82

Revenue Per Share

24.931

Quarterly Revenue Growth

0.044

The market value of Merck Company is measured differently than its book value, which is the value of Merck that is recorded on the company's balance sheet. Investors also form their own opinion of Merck's value that differs from its market value or its book value, called intrinsic value, which is Merck's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Merck's market value can be influenced by many factors that don't directly affect Merck's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine if Merck is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Merck Net Debt from 2010 to 2024

Latest Merck's Net Debt Growth Pattern

Merck Net Debt Regression Statistics

Merck Net Debt History

Other Fundumenentals of Merck Company

Merck Net Debt component correlations

About Merck Financial Statements

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY